SONY

Product Data Sheet

APC/Cyanine7 anti-human CD273 (B7-DC, PD-L2)

Catalog # / Size:	2327575 / 25 tests 2327580 / 100 tests
Clone:	MIH18
Isotype:	Mouse IgG1, κ
Immunogen:	Human B7-DC transfected cells
Reactivity:	Human
Preparation:	The antibody was purified by affinity chromatography and conjugated with APC/Cyanine7 under optimal conditions. The solution is free of unconjugated APC/Cyanine7 and unconjugated antibody.
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).
Workshop Number:	HCDM listed
Concentration:	Lot-specific



Human monocyte-derived dendritic cells were stained with CD273 (B7-DC

Applications:

Applications:	Flow Cytometry
Recommended Usage:	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes:	Additional reported applications (for the relevant formats) include: blocking[4,5], and immunohistochemistry in frozen sections[2] and paraffin-embedded formalin-fixed sections[6].
Application References:	1. Carreno BM, *et al.* 2002. *Annu. Rev. Immunol.* 20:29. 2. Ohigashi Y, *et al.* 2005. *Clin. Cancer. Res.* 8:2947.

Description:	CD273, known as B7-DC, is also called programmed death ligand 2 (PDL2). This ligand is a 25 kD type I transmembrane protein and a member of B7 family within the immunoglobulin receptor superfamily and is expressed on a subset of dendritic cells, liver and a small subset of macrophages as well as a few transformed cell lines. CD273 has been reported to be stimulatory on dendritic cells when cross-linked and to inhibit T cell activation upon engaging the PD-1 receptor. CD273 has also been reported to bind to an alternative receptor and to mediate T cell activation through such non-PD1 mediated interactions. Clone MIH18 is reported to block PDL2.
Antigen References:	1. Carreno BM, *et al.* 2002. *Annu. Rev. Immunol.* 20:29. 2. Ohigashi Y, *et al.* 2005. *Clin. Cancer. Res.* 8:2947.

Sony Biotechnology Inc. 1730 North First Street, San Jose, CA 95112 www.sonybiotechnology.com